156 related articles for article (PubMed ID: 16440809)
1. [Generalized erythema triggered by a rapid decrease of basophils in chronic myeloid leukemia treated with imatinib].
Sugito M; Tsukada J; Higashi T; Ohta T; Matsuura A; Kubota A; Mizobe T; Mouri F; Morimoto H; Tanaka Y
Rinsho Ketsueki; 2005 Nov; 46(11):1226-8. PubMed ID: 16440809
[TBL] [Abstract][Full Text] [Related]
2. [Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy].
Sumi M; Tauchi T; Shimamoto T; Sshida G; Nakajima A; Ito Y; Ohyashiki K
Rinsho Ketsueki; 2002 Sep; 43(9):868-70. PubMed ID: 12412295
[TBL] [Abstract][Full Text] [Related]
3. Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.
Ferrand H; Tamburini J; Mouly S; Bouscary D; Bergmann JF
Clin Infect Dis; 2005 Dec; 41(11):1684-5. PubMed ID: 16267747
[No Abstract] [Full Text] [Related]
4. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
[TBL] [Abstract][Full Text] [Related]
5. [Imatinib-induced DRESS].
Goldman J; Duval-Modeste AB; Lambert A; Contentin N; Courville P; Musette P; Joly P
Ann Dermatol Venereol; 2008 May; 135(5):393-6. PubMed ID: 18457727
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
[No Abstract] [Full Text] [Related]
7. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
[TBL] [Abstract][Full Text] [Related]
8. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
Woo SM; Huh CH; Park KC; Youn SW
J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
[No Abstract] [Full Text] [Related]
9. [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia].
Shimizu K; Kuroda H; Kida M; Watanabe H; Shirao S; Akiyama T; Fujimi A; Tanaka I; Sato T; Matsunaga T; Niitsu Y
Rinsho Ketsueki; 2005 Oct; 46(10):1152-5. PubMed ID: 16440780
[TBL] [Abstract][Full Text] [Related]
10. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
11. [Intestinal bleeding during the treatment of chronic myeloid leukemia with imatinib mesylate].
Yokote T; Akioka T; Nakayama S; Oka S; Hara S; Yamano T; Tsuji M; Hanafusa T
Rinsho Ketsueki; 2005 Sep; 46(9):1060-4. PubMed ID: 16440765
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate as a cause of acute liver failure.
Cross TJ; Bagot C; Portmann B; Wendon J; Gillett D
Am J Hematol; 2006 Mar; 81(3):189-92. PubMed ID: 16493605
[TBL] [Abstract][Full Text] [Related]
13. Imatinib: a designer drug, another cutaneous complication.
Dickens E; Lewis F; Bienz N
Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
[TBL] [Abstract][Full Text] [Related]
14. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
Breccia M; Cannella L; Frustaci A; Stefanizzi C; Levi A; Alimena G
Leuk Res; 2008 May; 32(5):835-6. PubMed ID: 17905431
[No Abstract] [Full Text] [Related]
15. Desensitization to imatinib in patients with leukemia.
Nelson RP; Cornetta K; Ward KE; Ramanuja S; Fausel C; Cripe LD
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):216-22. PubMed ID: 16937754
[TBL] [Abstract][Full Text] [Related]
16. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases.
Brazzelli V; Prestinari F; Roveda E; Barbagallo T; Bellani E; Vassallo C; Orlandi E; Passamonti F; Borroni G
J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S240-3. PubMed ID: 16227099
[TBL] [Abstract][Full Text] [Related]
17. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
[No Abstract] [Full Text] [Related]
18. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
19. Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.
Zaucha JM; Wyrowinska E; Prejzner W; Calbecka M; Hellmann A
Clin Lab Haematol; 2006 Jun; 28(3):208-10. PubMed ID: 16706939
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.
Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G
Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]